Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Cancer Immunology, Immunotherapy, 06/12/2012
Albertini MR et al. – The authors conclude that subsequent testing of hu14.18–IL2 should involve melanoma patients with minimal residual disease based on compelling preclinical data and the confirmed immune activation with some antitumor activity in this study.



